ZYLOX-TONBRIDGE MEDICAL TECHNOLOGY CO., LTD. Financials Zylox-Tonbridge Medical Technology Co., Ltd.
Equities
2190
CNE100004JD2
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.26 HKD | +0.98% |
|
-4.29% | -17.52% |
| May. 09 | Zylox-Tonbridge Medical Technology Co., Ltd. Announces Retirement of Hongze Liang as an Independent Non-Executive Director | CI |
| Mar. 22 | Zylox-Tonbridge Shrinks Loss by 31% in Fiscal 2023 | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6,907 | 3,769 | 3,704 | 3,053 | - | - |
| Enterprise Value (EV) 1 | 3,987 | 2,578 | 3,704 | 2,251 | 2,253 | 2,184 |
| P/E ratio | - | -33.4 x | -47.1 x | 42.8 x | 19.4 x | 11 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 38.8 x | 11.3 x | 7.02 x | 4.02 x | 2.82 x | 2.09 x |
| EV / Revenue | 22.4 x | 7.72 x | 7.02 x | 2.96 x | 2.08 x | 1.49 x |
| EV / EBITDA | -19.4 x | -13 x | - | 31 x | 12.6 x | 8.45 x |
| EV / FCF | - | -11.4 x | - | -15.4 x | -35.2 x | 75.3 x |
| FCF Yield | - | -8.77% | - | -6.49% | -2.84% | 1.33% |
| Price to Book | 1.95 x | 1.21 x | - | 1.01 x | 0.96 x | 0.88 x |
| Nbr of stocks (in thousands) | 332,401 | 332,401 | 327,566 | 323,938 | - | - |
| Reference price 2 | 20.78 | 11.34 | 11.31 | 9.423 | 9.423 | 9.423 |
| Announcement Date | 3/15/22 | 3/29/23 | 3/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 27.63 | 177.9 | 334.1 | 527.8 | 759.8 | 1,081 | 1,462 |
| EBITDA 1 | - | -205.9 | -198 | - | 72.65 | 178.5 | 258.6 |
| EBIT 1 | - | -212.5 | -208.4 | -156.5 | 51 | 160.5 | 296 |
| Operating Margin | - | -119.43% | -62.38% | -29.66% | 6.71% | 14.85% | 20.25% |
| Earnings before Tax (EBT) 1 | - | - | -113.6 | -78.73 | 76.33 | 171.3 | 295 |
| Net income 1 | - | - | -113.6 | -78.73 | 72 | 161.3 | 286.5 |
| Net margin | - | - | -33.99% | -14.92% | 9.48% | 14.93% | 19.6% |
| EPS 2 | -0.5200 | - | -0.3400 | -0.2400 | 0.2200 | 0.4867 | 0.8600 |
| Free Cash Flow 1 | - | - | -226.1 | - | -146 | -64 | 29 |
| FCF margin | - | - | -67.66% | - | -19.22% | -5.92% | 1.98% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | 11.21% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 10.12% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Announcement Date | 6/22/21 | 3/15/22 | 3/29/23 | 3/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | - | 2,919 | 1,191 | - | 802 | 800 | 868 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -226 | - | -146 | -64 | 29 |
| ROE (net income / shareholders' equity) | - | -11.2% | -3.64% | - | 2.36% | 4.76% | 7.61% |
| ROA (Net income/ Total Assets) | - | - | -3.49% | - | 2.1% | 4.37% | 6.75% |
| Assets 1 | - | - | 3,251 | - | 3,429 | 3,695 | 4,244 |
| Book Value Per Share 2 | - | 10.70 | 9.370 | - | 9.350 | 9.830 | 10.70 |
| Cash Flow per Share 2 | - | - | -0.2800 | - | 0.1200 | 0.3300 | - |
| Capex 1 | - | - | 135 | - | 98.3 | 99.7 | 91 |
| Capex / Sales | - | - | 40.33% | - | 12.94% | 9.22% | 6.22% |
| Announcement Date | 6/22/21 | 3/15/22 | 3/29/23 | 3/21/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
9.423
CNY
Average target price
14.14
CNY
Spread / Average Target
+50.06%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -17.52% | 422M | |
| +12.01% | 128B | |
| -7.76% | 11.26B | |
| +6.26% | 9.28B | |
| +35.53% | 5.42B | |
| +8.68% | 3.45B | |
| -8.89% | 2.8B | |
| -10.68% | 2.1B | |
| -10.77% | 1.98B | |
| -26.31% | 1.71B |
- Stock Market
- Equities
- 2190 Stock
- Financials Zylox-Tonbridge Medical Technology Co., Ltd.
